[Anti-TPO antibodies and screening of thyroid dysfunction in type 1 diabetic patients].
The diagnosis of thyroid dysfunction is often late in type 1 diabetic population. So, the aims of this study were 1) to evaluate the prevalences of thyroperoxydase (TPO) and thyroglobulin (Tg) autoantibodies detected by highly sensitive radioimmunological method in a cohort of 258 adult type 1 diabetic patients without evidence of clinical thyroid disease; 2) to determine whether or not measurement of TPO and/or Tg antibodies can identify subjects at risk of clinical or infraclinical thyroid dysfunction by measuring TSH in the entire group. TPO antibodies were found in 45 of the 258 diabetic patients (17%). The prevalence of TPO antibodies was not influenced by the following factors: gender, duration of disease, age at screening and at diabetes diagnosis, positivity of familial history. Tg antibodies were found in 19 patients (7%), including 13 cases with TPO antibodies. All patients without TPO antibody (n=213), including Tg-positive patients displayed TSH values in normal range. Among the 45 TPO-positive patients, 11 patients displayed infraclinical thyroid dysfunction. At the end of the 5-year follow-up, only 2/45 patients became anti-TPO negative. Thirteen of the 45 patients developed subclinical or clinical thyroid diseases (4 Graves'disease and 9 thyroiditis with hypothyroidism). By contrast, none of 45 TPO negative patients, sex and age matched with the TPO-positive patients, developed during follow-up anti-TPO positivity and/or infraclinical thyroid dysfunction. In conclusion, the determination of TPO antibodies by a highly sensitive method allows identifying diabetic patients with thyroid autoimmunity and at risk of subsequent impaired thyroid function, whatever age at diagnosis and diabetes duration. By contrast, anti-Tg determination did not give further information about subsequent thyroid dysfunction. In TPO antibody positive patients repeated thyroid clinical examination and TSH determination could be recommended to detect infraclinical thyroid dysfunction.
Maugendre
D
D
Service d'Endocrinologie et maladies métaboliques, CHU, Hôpital Sud, 16, bd de Bulgarie, 35056 Rennes, France. Didier.Maugendre@chu-rennes.fr
Guilhem
I
I
Karacatsanis
C
C
Poirier
J Y
JY
Leguerrier
A M
AM
Lorcy
Y
Y
Derrien
C
C
Sonnet
E
E
Massart
C
C
D000293:Adolescent; D000328:Adult; D000906:Antibodies / Q000097:blood*; D001327:Autoimmune Diseases / Q000097:blood / Q000175:diagnosis*; D015415:Biomarkers / Q000097:blood; D004796:Clinical Enzyme Tests; D003922:Diabetes Mellitus, Type 1 / Q000150:complications / Q000201:enzymology*; D005260:Female; D006801:Humans; D007453:Iodide Peroxidase / Q000097:blood / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D013954:Thyroglobulin / Q000097:blood / Q000276:immunology; D013959:Thyroid Diseases / Q000097:blood / Q000175:diagnosis*; D013974:Thyroxine / Q000097:blood; D014284:Triiodothyronine / Q000097:blood
D000906:Antibodies; D015415:Biomarkers; D014284:Triiodothyronine; D013954:Thyroglobulin; D007453:Iodide Peroxidase; D013974:Thyroxine